MedImmune wins $90M swine flu vax contract
MedImmune has received a $90 million order from the U.S. government for a live attenuated vaccine that can be used against the H1N1 outbreak. The vaccine developer says this could be the first of many new orders for a swine flu jab. And the company, the biotech arm of AstraZeneca, says it will begin shipping the first of 10 million doses of its seasonal flu vaccine in August. Report
Comments